Metastases - malecare.org

Can Bone Pain Predict Survival in Men with Metastatic Hormone-Refractory Prostate Cancer Treated with Docetaxel? What are the Implications?

A small study of 145 men with asymptomatic metastatic hormone-refractory prostate cancer (HRPC) was conducted to determine the benefit of starting early chemotherapy with docetaxel. Collected data were analyzed from these subjects who were treated with chemotherapy between February 2000 and June 2002 in one French center. The men were categorized into three groups according [...]

By Malecare|2009-03-16T08:11:28-04:00March 16th, 2009|Advanced Prostate Cancer, Drugs & Treatments, Metastases, Research, Uncategorized, Understanding APC|0 Comments

Additional Information On Yesterday’s Post About Alpharadin

Charles (Chuck) Maack, Prostate Cancer Advocate/Mentor from the Wichita Kansas Chapter of Us TOO sent me this follow-up to yesterday's post on Alpharadin. Interesting is this drug completed Phase II trials in Norway back in October 2007 involving 64 HRPC patients with more than twice as many patients receiving Alpharadin alive (10 of 33) two [...]

By Malecare|2021-02-17T10:45:33-05:00February 5th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Metastases, Uncategorized|0 Comments

Algeta, Completing A Successful Phase II Trial For Men With Bone Metastases Will Begin Enrolling US Survivors Into A Phase III Trial

Algeta ASA (OSE: ALGETA), has announced that it will begin to enroll US survivors into its Alsympca phase III trial evaluating Alpharadin (radium-223). Alpharadin is designed to be used as a treatment for bone metastases in prostate cancer survivors with hormone-refractory prostate cancer (HRPC). The announcement of the trial follows a successful end-of-phase II meeting [...]

By Malecare|2021-02-17T10:45:20-05:00February 4th, 2009|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, Metastases, Research, Uncategorized, Understanding APC|0 Comments

Thalidomide To Slow Down the Development of Metastatic Disease

Are you planning on becoming pregnant? If not, researchers from the Medical Oncology Branch of the National Cancer Institute, National Institutes of Health have reported a study successfully using thalidomide to slow down the progression of advanced prostate cancer. Thalidomide is a drug that was first synthesized in 1954 to be used as a sedative. [...]

By Malecare|2017-10-19T10:56:22-04:00January 22nd, 2009|Advanced Prostate Cancer, Drugs & Treatments, Metastases, Uncategorized, Understanding APC|0 Comments

A Priority FDA Review for Toremifene 80 mg for Bone Protection

GTx announced in a company media release that it has requested that the FDA consider its new drug application (NDA) for the use of toremifene 80 mg to prevent bone fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). GTx has asked for a priority review of its application stating that “there are [...]

By Malecare|2009-01-01T11:37:15-05:00January 1st, 2009|Advanced Prostate Cancer, Bone Mineral Density, Drugs & Treatments, FDA, Financial, Hormone Therapy, How We Live, Metastases, Politics of Cancer, Uncategorized|0 Comments